Current Status of Skin Cornification

정수일

㈜녹십자목암연구소

Cornified Cell Envelop (CE)

- CE is a 15 nm thick insoluble layer consists of protein and lipid lamella envelop that is formed under the newly formed lipid membrane in the upper layer of epidermis and keratinizing stratified epithelium.
- CE provides a protective mechanical and chemical barrier of our body.
- CE is maintained by continuous reproduction of inner living epidermal keratinocytes which undergo a process of terminal differentiation and the migrate to the surface as interlocking layers.

Cornified Cell Envelop (CE)

Three area of research data will be discussed in following order.

- Lipid Lamellae
- CE component proteins and assembly
- Crosslinking enzymes (TGases)

Lipid Lamellae (LL)Formation

- Intercellular LL in the stratum corneum constitute the barrier to water diffusion and may play a role in cohesion between corneccytes.
- LL arise from stacks of lamellar disks that are extruded from the granular cells and fuse edge to edge to form sheets.

Inducible Enzymes in Lipid Lamellar Formation:

- Ceramide: Serine palmitoyl transferase
 Glucose ceramide transferase
 ω-Hydroxylation (P450)
 β-Glucocerebrosidase (+Saposines)
- Cholestrol: HMG CoA reductase
 Cholestrol sulfo transferase
 Steroid sulfatase

Methods used for identifying the crosslinked Proteins in CE.

- For outer membrane side of CE, ceramide lipids were removed by mild alkaline hydrolysis and exposed proteins were analyzed. For cellular side the CE were fragmented and analyzed. Both CE were treated by limited proteolysis and peptides were isolated and sequenced.
- Exposed proteins were identified with respective antibodies.
- Synthetic Lipid Vesicle which is similar to plasma membrane lipids binds involucrin, TGase K, and ceramide, were used for crosslinking of ceramide to protein.

Name	Gene locus	Size (kDe)	Relative abundance in human foresidn CE	Cross-linking sites identified in vivo?
Involuciin Loriciin SPRs	1921 (EDC) 1921 (EDC) 1921 (EDC)			Yea (***)
Cycletin A Proclatin	3cen-q21 20q12-q13	12 10	2-6% < %	Yes Yes
(Pro)filaggrin Type II keratine Desmoplakin	1q21 (EDC) 12q13 6o21-ter	>400 56-60 330/250		Yes
Envoptakin Periptakin	17q25 16p13.3	210 - 1216 - 1		Yos Yes
S100 proteins Annexin I	1q21 (EDC) 9q12-q21,2			No see see

Loricrin

- 1 msyqkkqptp qppvdcvkts gggggggtg gggcgffggg gsgggssgs cgysgggys 61 gggcgggssg ggggggigc gggsggsvky sggggssggg sgcfssgggg sgcfssgggg sgggsgcfs sggggsgcfs sggggsgcfs gggsgcfssg fsggavcqs yggvssggs gggsgcfssg 181 ggggsvcgys gggsgggsc gggssggsg gyvssqqvtq tscapqpsyg ggssggggg 241 gsgcfssgg ggssgcggs sgigsgciis gggsvcggs sggggggssv ggsggkgvp 301 ichqtqqkqa ptwpsk
- * No tertiary structure(40% glycine)
- * Three regions contain crosslinking sites.
- * Molecules can be stretched.
- * 65 ~ 80% of CE.
- * TGase E(TGase 3) likely serves as crosslinking enzyme.
- * Fills the inner side of envelop

Involucrin

```
1 msqqhtlpvt lspalsqell ktvpppvnth qeqmkqptpl pppcqkvpve lpvevpskqe
61 ekhmtavkgl peqeceqqqk epqeqelqqq hweqheeyqk aenpeqqlkq ektqrdqqln
121 kqleeekkll dqqldqelvk rdeqlgmkke qllelpeqqe ghlkhleqqe gqlkhpeqqe
181 gqlelpeqqe gqlelpeqqe gqlelpeqqe gqlelpeqqe gqlelpeqqe gqlelpeqqe gqlelpeqqe gqlkyleqqe gqlkhldqqe
241 gqlelseqqe gqlkhleqqe gqlkhleqqe gqleqleeqe gqlkhleqqe gqlkhleqqe
301 kqpelpeqqm gqlkhleqqe gqpkhleqqe gqleqleeqe gqlkhleqqe gqlehlehqe
361 gqlglpeqqv lqlkqlekqq gqpkhleeee gqlkhlvqqe gqlkhlvqqe gqleqqerqv
421 ehleqqvgql khleeqegql khleqqqqql evpeqqvqqp knleqeekql elpeqqegqv
481 khlekqeaql elpeqqvqqp khleqqekhl ehpeqddqql khleqqegql kdleqqkqql
541 eqpvfapapg qvqdiqpalp tkgevllpve hqqqkqevqw ppkhk
```

- * The outer layer protein of envelop that are in contact with lipid laminae
- * Contains unique ten residue TGase substrate sequences that are repeated 39 times in tandem
- * Membrane-bound TGase K(TGase 1) specifically catalyzes crosslinking of ceramide and other proteins to nvolucrin

Small Proline-Rich Protein

- 1 mnsqqqkqpc tpppqqqqq vkqpcqpppq epcipktkep cqpkvpepch pkvpepcqpk 61 ipepcqpkvp epcpstvtpa paqqktkqk
- * 6 X Octapeptide TANDEM REPEATS
 - 1 mssyqqkqtf tpppqlqqqq vkqpsqpppq eifvpttkep chskvpqpgn tkipepgctk
 - 61 vpepgctkvp epgctkvpep gctkvpepgc tkvpepgctk vpepgytkvp epgsikvpdq
 - 121 qfikfpepga ikvpeqgytk vpvpgytklp epcpstvtpg paqqktkqk
- * CE precursor; contains 14 internal octapeptide
 repeats; head and tail domains are substrates for
 transglutaminase-mediated cross-linking
- * 4 ~ 5% of CE & linking with Loriclin

Transglutaminases (TGases)

TGases catalyze an acyl transfer reaction involving γ -carboxamide group of pepetide bound glutamine residue to primary amino or hydroxyl group (nucleophile) of aliphatic chain (i.e. lysine, ω -OH ceramide).


- Isopeptide bond [$N^{\epsilon}(\gamma\text{-glutamyl})$ lysine] formed between peptides induce very stable polymer formation.
- Ester bond [O^ω(γ-glutamyl)ceramide ester] formed between peptide and lipid molecules allow stable lipid-protein lamellae.

Transglutaminase K (TGase 1)

- 106 kD membrane-bound zymogen
- Distributed in keratinocytes(ectodermal), chondrocytes(mesemchy-mal) cellular origin
- Membrane anchored by myristylation and palmitylation
- Activated by proteolysis of two cleavage sites but held together(10, 67 & 30)
- Heavily expressed in granulocyte
- Catalyze the crosslinking reaction of ω -OH group of ceramide to glutamine residue of Involucrin as well as N^{ϵ}(γ -glutamyl)lysine crosslinks

Transglutaminase E (TGase 3)

- 77.8 kD cytoslic zymegoen
- Activated by proteolysis, organic solvent, heat etc.
- Mainly expressed in Stratum Granulosum and functions in Stratum Corneum
- Catalyze crosslinking reactions of numerous cytosolic proteins to loricrin : Spr1,2,3, cystatin, elafin etc.
- Catalytically most active and stable TGase



Summary

Biochemical, enzymatic, immunological, and morphological evidences on ceramide and other lipids lamellae formation, assembly of component proteins of CE and expression and distribution of TGases provided better understanding of CE formation. Pathophysiology of some of the genetic disease is beginning to be clarified. Hope we can utilize the information gained in understanding CE formation would expedite the development of patient treatment processes.

